Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Coeur Commences Drilling at Silver North's Tim Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(11)
•••
Comment by Jmk2454on Jul 06, 2019 9:13pm
63 Views
Post# 29892838

RE:RE:Ask Mr. Google this question (or Mrs.) LOL

RE:RE:Ask Mr. Google this question (or Mrs.) LOL
Chamler101 wrote:
Exactly, it takes about 10 seconds of "research" to figure out that reverse splits are a mixed bag. For Penny to suggest that it is unequivocally bad news for a stock speaks volumes. We should dispell the notion he is manically posting for any other purpose but his own gain (whether that be monetary or entertainment).
If you are holding this as anything but a risky investment I would suggest rethinking this, only gamble (yes, gamble) what you comfortably lose. 
I'm holding, and hoping, good luck to all.


Thank you for stating this. Every time Penny quotes the same google search comment that anybody can find that states a RS is purely negative, I chuckle to myself and think there is an agenda there. While I’m not crazy about a RS, we don’t even know that it’s going to happen. It’s just going to be voted on. And if it happens, it happens. As you say, don’t invest what you can’t afford to lose, but I believe Kalytera may be a winner. Again, good luck to all - let’s hope for some great upcoming news!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities